Regen Biopharma Inc 's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Regen Biopharma Inc 's ROA in the third quarter of 2026?
Regen Biopharma Inc recorded a cumulative net loss of $-2 million during 12 months ending in the third quarter of 2026, resulting in a negative return on assets (ROA) of -138.73%.

However, within the Healthcare sector 917 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4627, from total ROA ranking in the second quarter of 2026 at 5393.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) III. Quarter	(Mar 31 2026) II. Quarter	(Dec 31 2025) I. Quarter	(Sep 30 2025) IV. Quarter	(Jun 30 2025) III. Quarter
Y / Y Total Assets Change	2216.93 %	53.52 %	70.5 %	-93.83 %	26.1 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-2	-2	-2	-2	-1
Return On Assets (TTM)	-138.73 %	-599.4 %	-960.97 %	-873.32 %	-62.55 %
RGBP's Total Ranking	# 4627	# 5393	# 4783	# 4803	# 4879
Total Assets (TTM) in million	5	0	0	0	0
Seq. Total Assets Change	1810.77 %	-5.27 %	0 %	28 %	26.61 %
Seq. Net Income Change	-	-	-	-	-

RGBP's 5 Years Annual ROA >> Back to RGBP Management Effectiveness >> Compare RGBP ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 439
Sector	# 918
Overall	# 4596

Return On Assets Statistics
High	Average	Low
11244.45 %	-438.94 %	-6555.41 %
(Mar 31 2023)		(Mar 31 2022)

Financial Statements
Regen Biopharma Inc 's Assets	$ 5 million	RGBP's Balance sheet
Regen Biopharma Inc 's Income	$ -1 million	Quarterly RGBP's Income Statement
RGBP's Income by Division		See RGBP's Income by Division

Annual Return On Assets	(Sep 30 2025) FY 2025	(Sep 30 2024) FY 2024	(Sep 30 2023) FY 2023	(Sep 30 2022) FY 2022	(Sep 30 2021) FY 2021
Y / Y Total Assets Change	70.5 %	-54.45 %	-36.74 %	-89.99 %	4431.41 %
Total Assets in million	0	0	0	1	6
Y / Y Net Income Change	-	-	-54.04 %	-	-
Net Income in million	-1	-1	1	2	-7
Annual Return On Assets	-464.04 %	-414.85 %	289.41 %	398.38 %	-121.19 %

RGBP's 5 Years Annual ROA >> Back to RGBP Management Effectiveness >> Compare RGBP ROA to its Competitors

More Return On Assets Ratios
RGBP's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
RGBP's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for RGBP's Competitors
Subscribers only: Roa for Regen Biopharma Inc 's Suppliers
Subscribers only: Return On Assets for RGBP's Customers

You may also want to know
RGBP's Roi	RGBP's Inventory Turnover Ratio	RGBP's Growth Rates	RGBP's Dividend Comparisons
	RGBP's Profitability Ratios	RGBP's Asset Turnover Ratio	RGBP's Dividend Growth
RGBP's Roe	RGBP's Valuation Ratios	RGBP's Financial Strength Ratios	RGBP's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-08-18T07:46:10+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.